Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Patients presenting a deterioration of the general state (performance status [PS] 2-3),
constitute a population which needs an adapted treatment. An analysis was made of the
evolution of PS 2 patients included in the Eastern Cooperative Oncology Group (ECOG) 1594
trial which evaluated associations of new cytotoxic agents (gemcitabine, paclitaxel,
docetaxel) with cisplatin. During this trial, the inclusion of these patients stopped due to
the occurrence of toxicities more frequent than in the other populations (PS 0-1). At the end
of this study, with the analysis of total toxicity, this one was not higher than that noted
in the groups of PS 0 and 1 patients. In the population of PS 2 patients, 5 deaths had been
noted, but the analysis showed that only 2 were due to the treatment. It was noted that the
lower survival compared to the others was related to the disease and not to the treatment.
These patients are often symptomatic and need palliative treatment. The benefit of
chemotherapy should not be denied. They should profit from a monochemotherapy with the new
cytotoxic agents, without associated platinum salt.
Phase:
Phase 2
Details
Lead Sponsor:
Intergroupe Francophone de Cancerologie Thoracique